Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
News Aug 26, 2011
The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
Commenting on the announcement, Erik Walldén, CEO at Gyros, said, “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry. Expansion into the Asian markets through an experienced and respected network of distributors will ensure the highest possible standards of service and support for customers interested in our products, which we see as one of the key factors for commercial success in this region. Having recently signed with GE Healthcare Japan, we are very pleased to extend our collaboration into China, Taiwan and Hong Kong through such a well-established supplier.”
Duncan Yu, General Manager, Life Sciences of GE Healthcare Greater China , added, “We are delighted to have signed this agreement with Gyros which will help us further expand our offering of value-added and innovative technologies to the rapidly growing biopharmaceutical industry in China, Taiwan and Hong Kong. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry including Biacore™ and MicroCal™ systems.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE